Insogna Awarded Shared Instrument Grant
Karl Insogna, MD, FACP, Ensign Professor of Medicine (Endocrinology); director, Yale Bone Center; and associate director, Yale Center for X-Linked Hypophosphatemia, has received funding from Yale University’s Core Facilities Request for Equipment Replacement and Upgrade Program to acquire an UltraFocus digital x-ray cabinet by Faxitron®.
Experimental drug that targets liver fat may help prevent diabetes
An experimental drug has reversed the build-up of fat in the liver and lowered blood levels of fatty substances including cholesterol in non-human primates. The build-up of fat in the liver, known as non-alcoholic fatty liver disease, affects 1 in 3 people and can lead to type 2 diabetes as well as heart and kidney disease.
Burosumab Shows Sustained Efficacy in Rare Inherited Rickets
Burosumab (Crysvita, Ultragenyx), an anti-FGF23 monoclonal antibody, shows long-term safety and efficacy out to almost 2 years in the treatment of X-linked hypophosphatemia (XLH), a rare, inherited form of rickets, according to the latest findings from a phase 3 clinical trial.
Treating adolescent obesity: The evidence behind behavioral, pharmacological, and weight loss surgery options
SILVER SPRING, Md.--As rates of adolescent obesity continue to rise, choice of treatment needs to be guided by the severity of obesity, psychosocial factors, comorbidities and patient's age and pubertal status, according to a new paper published online in the Journal of the American Medical Association (JAMA).
DAPA-HF analyses provide further insights into dapagliflozin efficacy
Analyses of metabolic, biomarker, and other outcomes from the DAPA-HF trial presented at the 55th EASD Annual Meeting in Barcelona, Spain, provide additional insights into the efficacy of dapagliflozin in patients with heart failure (HF).
Use of insulin among older adults with type 2 diabetes not aligned with national guidelines
Patients with type 2 diabetes who were in poor health were more likely to continue taking insulin after age 75 than their counterparts in better health, according to Kaiser Permanente research published today in JAMA Internal Medicine.
A man who switched to more affordable insulin died. Here's what happened in the viral story
An uninsured man with Type I diabetes switched from prescription insulin to a less expensive over-the-counter product last year. He died months later due to complications from the disease, according to his obituary.
Herold Is Designated C.N.H. Long Professor
Kevan Herold, MD, newly named as C.N.H. Long Professor of Immunobiology and of Medicine, conducts research on the basis for autoimmune diseases and develops new therapies based on these studies. His focus has largely been in the field of autoimmune Type 1 diabetes.